Valneva SE
NASDAQ: VALN0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Global Select
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Thomas Lingelbach
- Employees
- 713
- Headquarters
- Saint-Herblain, France
- IPO year
- 2021
- Market cap
- $495.9M
- Website
- https://valneva.com
Loading VALN…
Loading profile data…Frequently asked questions about VALN
What does Valneva SE (VALN) do?
Valneva SE operates as a specialized biopharmaceutical company, concentrating its efforts on developing and bringing to market preventative vaccines for infectious diseases where current medical options are insufficient. Its portfolio of commercial travel vaccines includes IXIARO, an inactivated vaccine derived from Vero cell culture, which prov...
Where does VALN trade?
Valneva SE (VALN) trades on the NASDAQ Global Select.
What sector is VALN in?
Valneva SE (VALN) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Valneva SE?
Thomas Lingelbach is the chief executive officer of Valneva SE (VALN).
Where is Valneva SE headquartered?
Valneva SE is headquartered in France.
Does VALN pay a dividend?
Valneva SE (VALN) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did VALN go public?
Valneva SE (VALN) completed its initial public offering in 2021.
Is VALN an ADR?
Yes — VALN is an American Depositary Receipt; its underlying shares trade on a non-US exchange. Valneva SE reporting and dividends follow the underlying issuer.